Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …
Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system,
which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has …
which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has …
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Background HER2 is overexpressed or amplified in a subset of biliary tract cancer.
Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited …
Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited …
[HTML][HTML] Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma
We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …
Cholangiocarcinoma—novel biological insights and therapeutic strategies
In the past 5 years, important advances have been made in the scientific understanding and
clinical management of cholangiocarcinoma (CCA). The cellular immune landscape of CCA …
clinical management of cholangiocarcinoma (CCA). The cellular immune landscape of CCA …
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Background Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the
pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of …
pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of …
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus …
Background The prognosis of patients with advanced biliary tract cancer who have
progressed on gemcitabine plus cisplatin is dismal. We aimed to investigate the efficacy and …
progressed on gemcitabine plus cisplatin is dismal. We aimed to investigate the efficacy and …
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Abstract Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in
FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions …
FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions …
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Cholangiocarcinoma constitutes a heterogeneous group of malignancies that can emerge at
any point of the biliary tree. Cholangiocarcinoma is classified into intrahepatic, perihilar and …
any point of the biliary tree. Cholangiocarcinoma is classified into intrahepatic, perihilar and …